Comparative Analysis of Safety and Efficacy Profiles of Different COVID-19 Vaccines
Keywords:
COVID-19; vaccine safety; mRNA; viral vector; protein subunitAbstract
Background: The SARS-CoV-2 pandemic and the COVID-19 virus, has presented unprecedented worldwide wellness challenges, necessitating urgent vaccine development and deployment. The emergence of multiple vaccine platforms has required comprehensive evaluation of their real-world performance.
Objectives: The purpose of this study was to evaluate the effectiveness, protection, and practical outcomes of four separated COVID-19 immunization platforms: mRNA, viral vector, protein subunit, and inactivated.
Methods: cross-sectional study was conducted involving 75 vaccinated individuals (61 mRNA recipients, 14 non-mRNA recipients), complemented by a systematic review of published literature. Demographic analysis revealed the cohort was predominantly young adults (56% aged 18-25) and female (68%), reflecting broader vaccination trends.
Results: This study compared four COVID-19 vaccine platforms. mRNA vaccines showed highest efficacy (94-95%), lowest breakthrough infections (21.3% vs 35.7% for others), and strong severe disease protection, but more side effects (62.3%).
Conclusion: vaccines are crucial for reducing the risk of pandemics.
References
Habib HM, Ibrahim S, Zaim A, Ibrahim WH.. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and otheriron chelators. Biomed Pharmacother. 2021;136:111228.
World Health Organization. Coronavirus (COVID-19) dashboard data table. Available from: https://covid19.who.int/. Accessed March 16, ,2022.
Li Q, Guan X, Wu P. Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207.
Zhu N, Zhang D, Wang W. China Novel Coronavirus Investigating and Research Team. A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(08):727–733.
Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)-China. China CDC Weekly. 2020;2:113–122.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
Cowling BJ, Leung GM. Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak. Euro Surveill. 2020;25.
World Health Organization (WHO) - Iraq Situation Reports (2021):WHO regularly published updates on Iraq's COVID-19 cases, includingthe impact of the Delta variant. Available at: https://www.who.int/countries/irq84.
Osman K, Mundodan J, Chowdhury J, et al. Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12-17 Years against COVID-19 Infection in Qatar. Vaccines (Basel). 2023;11(10):1522.
van der Heiden, M., Shetty, S., Bijvank, E. et al. Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial. Nat Commun 15, 6603 (2024).
Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020;27:225–228.
Zintel S, Flock C, Arbogast AL, Forster A, von Wagner C, Sieverding M. Gender differences in the intention to get vaccinated against COVID19: a systematic review and meta-analysis. Z Gesundh Wiss. Published online January 7, 2022.
Rosenblum HG, Gee J, Liu R, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect Dis. 2022;22(6):802-812.
Guo F, Adekanmbi V, Hsu CD, Polychronopoulou E, Berenson AB. One dose versus two doses of COVID-19 vaccine for the prevention of breakthrough infections among people previously infected with SARSCov-2. J Med Virol.2024;96(1):e29391
CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(21):792-793.
Zhang M, Liang Y, Yu D, et al. A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant. Int J Biol Sci. 2022;18(2):889-900.
Bruxvoort KJ, Sy LS, Qian L, et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. Lancet Reg Health Am. 2022;6:100134
Yasmin F, Najeeb H, Naeem U, et al. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis. 2023;11(3):e807.
Chen PW, Tsai ZY, Chao TH, Li YH, Hou CJ, Liu PY. Addressing vaccine‐induced immune thrombotic thrombocytopenia (Vitt) following covid‐19 vaccination: a mini‐review of practical strategies. Acta Cardiol Sin. 2021;37(4):355‐364.
Novak N, Tordesillas L, Cabanillas B. Adverse rare events to vaccines for COVID‐19: from hypersensitivity reactions to thrombosis and thrombocytopenia. Int Rev Immunol. 2022;41(4):438‐447.
Koh JS, Hoe RHM, Yong MH, et al. Hospital‐based observational study of neurological disorders in patients recently vaccinated with COVID‐19 mRNA vaccines. J Neurol Sci. 2021;430:120030.
Alamer E, Alhazmi A, Qasir NA, et al. Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia. Vaccines (Basel). 2021;9(11):1297
Finsterer J. A Case Report: Long Post-COVID Vaccination Syndrome During the Eleven Months After the Third Moderna Dose. Cureus. 2022;14(12):e32433
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Al-Qadisiyah Journal for Biomedical and Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
